May 28, 2026: The Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents With HIV have been updated. Community-Acquired Bacterial Pneumonia Hepatitis B Virus Infection Malaria Mycobacterium avium Complex Pneumocystis pneumonia Syphilis These guidelines are published in an electronic format and updated as changes occur in prevention and treatment science. All updates are…
May 27, 2026: The Panel on Antiretroviral Guidelines for Adults and Adolescents (the Panel) updated the Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents With HIV. For a comprehensive list of recent updates, please see What’s New in the Guidelines. The updates to the guidelines are outlined below. In March 2026, an updated American College…
April 23, 2026: The Guidelines for the Prevention and Treatment of Opportunistic Infections in Children With and Exposed to HIV have been updated. Mycobacterium avium Complex Disease Varicella-Zoster Virus Disease These guidelines are published in electronic format and updated as changes occur in prevention and treatment science. All updates are developed by the subject matter groups listed in Appendix…
Eskenazi Health Infectious Diseases Clinic (IDC) in Indianapolis received the 2025 Quality Award for increasing cervical cancer screenings among RWHAP clients from 43.8% to 65.7% through a data-driven QI project. By implementing on-site gynecological services, EMR-based patient outreach, and addressing root causes, the team successfully improved preventative care for people with HIV. Congratulations to MATEC…
Immunizations for Preventable Diseases in Adults and Adolescents With HIV February 25, 2026: The Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents With HIV have been updated. Varicella-Zoster Virus Disease These guidelines are published in an electronic format and updated as changes occur in prevention and treatment science. All updates are developed by the subject…
9-22-2025: CDC published new Clinical Recommendations for twice-a-year injectable lenacapavir as an additional option for HIV prevention in the United States. The U.S. Food and Drug Administration approved injectable lenacapavir, a prescribed medication, for HIV pre-exposure prophylaxis (PrEP) in June 2025. This is a significant step forward in expanding prevention options and reflects decades of research, partnership,…
9-25-25: The Panel on Antiretroviral Guidelines for Adults and Adolescents (the Panel) updated the Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents With HIV. For a comprehensive list of recent updates, please see What’s New in the Guidelines. The updates to the guidelines are outlined below. New Chapter Added to the Guidelines (Five Sections) These guidelines are…
9-30-2025: The Panel on Antiretroviral Therapy and Medical Management of Children Living With HIV has reviewed and updated sections in the Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection. When to Initiate Antiretroviral Treatment in Children With HIV Infection Management of Children Receiving Antiretroviral Therapy Special Considerations for Antiretroviral Therapy Use in Adolescents…
July 15, 2025: The Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents With HIV have been updated. Cytomegalovirus Disease Herpes Simplex Virus Immunizations for Preventable Diseases in Adults and Adolescents With HIV Mpox Table 4: Significant Pharmacokinetic Interactions Between Drugs Used to Treat or Prevent Opportunistic Infections Talaromycosis (formerly Penicilliosis) These guidelines…
June 12, 2025: The Panel on Treatment of HIV During Pregnancy and Prevention of Perinatal Transmission has updated the Recommendations for the Use of Antiretroviral Drugs During Pregnancy and Interventions to Reduce Perinatal HIV Transmission in the United States guidelines sections to address new data and publications where relevant. Key updates are summarized below. All revisions are…